New cancer pill tested in first human study
NCT ID NCT05478486
First seen Feb 04, 2026 · Last updated May 01, 2026 · Updated 15 times
Summary
This early-stage trial tested a new oral drug, MSP008-22, for safety and tolerability in 7 adults with advanced solid tumors (breast, ovarian, prostate, head and neck cancers). The main goal was to find the highest safe dose and identify side effects. This is a first step to see if the drug is safe enough for further testing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) of TATA Memorial Centre
Navi Mumbai, Maharashtra, 410210, India
Conditions
Explore the condition pages connected to this study.